pocketful logo
ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

NSE: ERIS BSE: 540596

₹1349.30

(-0.13%)

Thu, 12 Mar 2026, 00:33 am

mtf coin illustrationMTF 5x

ERIS Lifesciences Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    18692.33

  • Net Profit

    374.67

  • P/B

    6.76

  • Sector P/E

    32.85

  • P/E

    54.84

  • EV/EBITDA

    20.81

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.89

  • ROCE (Industry)

    16.43

  • RONW (Industry)

    14.36

  • ROE

    13.77

  • ROCE

    13.29

  • Debt/Equity

    0.97

  • EPS (TTM)

    32.10

  • Dividend Yield

    0.54

  • Book Value

    253.71

  • Interest Cover

    3.11

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (7.5x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (11x coverage).
  • Eris Lifesciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Eris Lifesciences's earnings are expected to exceed the low risk growth rate next year.
  • Eris Lifesciences is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
thumbs up icon

Cons

  • Eris Lifesciences only just started paying a dividend, it is too early to tell if payments are increasing.
  • It is too early to tell whether Eris Lifesciences has stable dividend payments.
  • Eris Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Eris Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Eris Lifesciences is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters54.8554.8554.8454.8554.86
FII6.857.218.408.438.35
DII20.3219.3618.1718.0718.06
Public17.9918.5718.5918.6618.72
Government00000

Read More

Technical Analysis

RSI

43.10

MACD

-20.84

50 DMA

1417.99

200 DMA

1599.97

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1826.771613.971486.131401.171273.331188.37975.57
Fibonacci1613.971532.681482.461401.171319.881269.661188.37
Camarilla1416.821397.311377.811401.171338.791319.291299.78

Pivots Level: Classic

R3

+425.60

1826.77

R2

+212.80

1613.97

R1

+84.97

1486.13

1401.17
1401.17
Pivot Point
LTP: 1349.30

S1

-127.83

1273.33

S2

-212.80

1188.37

S3

-425.60

975.57

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1356.38

  • 20-EMA

    1370.42

  • 30-EMA

    1386.32

  • 50-EMA

    1418.66

  • 100-EMA

    1478.12

  • 200-EMA

    1503.04

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results
30 Jun 2025agm
07 Feb 2025dividend₹7.35 Dividend /Share13 Feb 2025
13 Jan 2025dividendInterim Dividend - Rs. - 7.3513 Feb 2025
04 Sept 2024agm
17 Aug 2024agmAnnual General Meeting18 Sept 2024
15 Aug 2023agmAnnual General Meeting18 Sept 2023
07 Aug 2023agm
05 Aug 2022dividend₹7.35 Dividend /Share16 Aug 2022
23 Jul 2022agmAnnual General Meeting25 Aug 2022

Read More

Peer Comparison

ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

ERIS Lifesciences Ltd About

ERIS Lifesciences manufactures, markets, and sells generic drugs. The Company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets. Eris Lifesciences also focuses on hypertension, anti-diabetes, metabolic disorders, lipid lowering, and therapeutic areas. Eris Lifesciences serves the pharmaceutical markets in India.

Industry

Pharmaceuticals - Indian - Formulations

Founded

2007

Headquarters

CEO

Amit Indubhushan Bakshi

Employees

Contact

Website icon

Website

http://www.eris.co.in

Email icon

Email

complianceofficer@erislifesciences.com

Phone icon

Phone

91-79-30451000

Location icon

Location

8th Floor Commerce House -IV, Prahladnagar 100 FT Road, Ahmedabad, Gujarat, 380015

Read More

ERIS Lifesciences Ltd Company History

YearHistory
2016
  • The Company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited.
  • The Company acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • The Company acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017
  • The Company was converted to a public limited company and its name was changed to Eris Lifesciences Limited.
  • The Company acquired the trademarks UNION, REUNION, and BON UNION.
  • A fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 2, 2017.
2022
  • Eris entered the dermatology therapy segment through the acquisition of Oaknet Healthcare for INR 6,500 million.
2023
  • Eris acquired the Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India.
2024
  • The Company acquired a 30% stake in Levim Lifetech Private Limited.
  • The Company acquired a 100% stake in Eris Pharmaceuticals Private Limited.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
RAKESH SHAHSell2000000135003 Oct 2024
MOTILAL OSWAL FINANCIAL SERVICES LIMITEDBuy20790001350.1803 Oct 2024
EMERALD INVESTMENTS LIMITEDSell9886882120122 Aug 2024
INFINITY PARTNERSBuy9886882120122 Aug 2024
RAKESH SHAHSell20000001000.1215 Jul 2024
FRANKLIN TEMPLETON MUTUAL FUNDBuy10942011000.0415 Jul 2024
BHIKHALAL CHIMANLAL SHAHSell820000912.531 Jan 2024
BHIKHALAL CHIMANLAL SHAHSell1280000913.0931 Jan 2024
SHAH RAKESHSell200000078331 Jul 2023
PLUTUS WEALTH MANAGEMENT LLPBuy100000078331 Jul 2023

Read More

ERIS Lifesciences Ltd News

Eris Lifesciences to Participate in Investec Conference

Eris Lifesciences management will participate in Investec India Promoter & Founder Conference 2026 on March 10, 2026 in Mumbai through physical meetings with investors.

05 Mar 2026

stocks

Eris Lifesciences Fined ₹1.30 Lakh by BSE, NSE

Eris Lifesciences faces regulatory fines totaling ₹1.30 lakh from BSE and NSE for non-compliance with board composition requirements due to completion of Independent Director's term.

28 Feb 2026

stocks

Eris Lifesciences Partners with Natco for Semaglutide

Eris Lifesciences announces strategic alliance with Natco Pharma to launch semaglutide in the Indian market, expanding diabetes treatment portfolio.

24 Feb 2026

co actions results

Eris Lifesciences Q3 FY26 Results Show Strong Growth

Eris Lifesciences reported consolidated revenue of ₹807.45 crore for Q3 FY26, up 11.00% YoY. Net profit reached ₹108.83 crore with exceptional items impacting results due to new labour codes.

13 Feb 2026

co actions results

Eris Lifesciences Board Meet Set for Feb 13, 2026

Eris Lifesciences has scheduled its board meeting for February 13, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.

06 Feb 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800